Orion Corporation (B)

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

X6002Y112

SEDOL

B17NY40

CIK

N/A

orion.fi

LEI:

FIGI: BBG000BZR2W0

ORNBV

Orion Corporation (B)

GICS: 35202010 · Sector: Health Care · Sub-Sector: Health Care

PROFILER

NAME

Orion Corporation (B)

ISIN

FI0009014377

TICKER

ORNBV

MIC

XHEL

REUTERS

ORNBV.HE

BLOOMBERG

ORNBV FH

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

GlobeNewswire is an important news source that provides investors with company-related information. In particular, it deals with events that may be relevant to the listing of companies or tradable financial instruments. You can access the complete overview of all reports via this link.

Thu, 19.12.2024

ORION CORPORATION
STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS
19 DECEMBER 2024 at 19.00 EET

Research & Analysis

Wed, 18.12.2024

ORION CORPORATION
PRESS RELEASE
18 DECEMBER 2024 at 17.00 EET

Research & Analysis

Thu, 12.12.2024

ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
12 DECEMBER 2024 at 20.30 EET

Research & Analysis

Wed, 27.11.2024

ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
27 NOVEMBER 2024 at 9.00 EET

Research & Analysis

Fri, 22.11.2024

Orion Research Foundation grants EUR 1,109,000 for research in 2025

Research & Analysis

Tue, 19.11.2024

ORION CORPORATION
INVESTOR NEWS
19 NOVEMBER 2024 at 18.30 EET

Research & Analysis

Fri, 01.11.2024

ORION CORPORATION
MANAGERS’ TRANSACTIONS
1 NOVEMBER 2024 at 9.45 EET

Research & Analysis

Tue, 29.10.2024

ORION CORPORATION
INTERIM REPORT 1–9/2024
29 OCTOBER 2024 at 12:00 EET

Research & Analysis

Thu, 24.10.2024

ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
24 OCTOBER 2024 at 19.50 EEST

Research & Analysis

Tue, 15.10.2024

ORION CORPORATION
PRESS RELEASE
15 OCTOBER 2024 at 9.00 EEST

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

SMART * AD

P R O D U C T S U G G E S T I O N S

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Orion Corporation (B)

Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction

142,701 Orion Corporation A shares converted into B shares

Orion Research Foundation grants EUR 1,109,000 for research in 2025

Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies

Orion Corporation: Managers’ transactions – Henrik Stenqvist

Orion Group Interim Report January–September 2024

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024

Newsletter